688046.SHG Gempharmatech Co. Ltd. A
- Market cap
- CNY 12.6B
- P/E
- 54.7x
- P/B
- 4.91x
- ROE
- 9.8%
- Dividend yield
- 0.49%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688046.SHG undervalued?
Graham numberThe Graham number of Gempharmatech Co. Ltd. A cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gempharmatech Co. Ltd. A fundamental analysis
No fundamental analysis for Gempharmatech Co. Ltd. A yet.
Gempharmatech Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gempharmatech Co. Ltd. A
GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, knock-in mouse, point-mutation mouse, transgenic mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testin…
Full company profileGempharmatech Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gempharmatech Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 193M | 262M | 394M | 517M | 622M | 687M | 793M | 919M |
| Gross Profit | 129M | 189M | 293M | 369M | 421M | 426M | 509M | 598M |
| Operating Income | 49.6M | 97.7M | 151M | 172M | 166M | 122M | 182M | 255M |
| EBITDA | 54.5M | 109M | 173M | 213M | 218M | 208M | 259M | 255M |
| Net Income | 34.7M | 76.4M | 125M | 165M | 159M | 110M | 143M | 222M |
| EPS | 0.10 | 0.21 | 0.30 | 0.40 | 0.39 | 0.27 | 0.35 | 0.54 |
| Balance Sheet | ||||||||
| Total Assets | 388M | 883M | 1.05B | 2.25B | 2.58B | 2.57B | 2.87B | 2.84B |
| Total Liabilities | 148M | 226M | 269M | 276M | 453M | 438M | 638M | 573M |
| Shareholders' Equity | 240M | 657M | 786M | 1.98B | 2.12B | 2.13B | 2.23B | 2.27B |
| Cash & Short-term Investments | 222M | 524M | 294M | 422M | 560M | 701M | 487M | 323M |
| Cash Flow | ||||||||
| Operating Cash Flow | 65.1M | 130M | 113M | 106M | 117M | 90.3M | 227M | - |
| Capital Expenditure | 45.7M | 167M | 89.1M | 190M | 206M | 114M | 105M | 71.7M |
| Free Cash Flow | 19.5M | -37.3M | 24.2M | -84.3M | -89.3M | -23.4M | 122M | 104M |
| Ratios | ||||||||
| ROE | 14.4% | 11.6% | 15.9% | 8.3% | 7.5% | 5.1% | 6.4% | 9.8% |
| ROA | 9.0% | 8.7% | 11.8% | 7.3% | 6.2% | 4.3% | 5.0% | 7.8% |
| Net Profit Margin | 18.0% | 29.2% | 31.7% | 31.9% | 25.5% | 16.0% | 18.0% | 24.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Gempharmatech Co. Ltd. A dividends
- Dividend yield
- 0.49%
- Forward dividend
- 0.32 CNY
- Payout ratio
- 42.9%
- Ex-dividend date
- Oct 22, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 61.2M | 0.15 | 42.9% |
| 2024 | CNY 80.1M | 0.20 | 73.0% |
| 2023 | CNY 17.9M | 0.04 | 11.2% |
| 2022 | CNY 284K | 0.00 | 0.2% |
| 2021 | CNY 680K | 0.00 | 0.5% |
| 2020 | CNY 672K | 0.00 | 0.9% |
| 2019 | CNY 236K | 0.00 | 0.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Gempharmatech Co. Ltd. A
- Insiders 59.53%
- Institutions 15.00%
- Public & others 25.47%
- Shares outstanding 410M
- Free float 179M
Gempharmatech Co. Ltd. A company profile
- Company name
- Gempharmatech Co. Ltd. A
- Ticker
- 688046.SHG
- ISIN
- CNE100005964
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,590
- Fiscal year end
- December
- Address
- No. 12 Xuefu Road, Nanjing, China, 210032
- Phone
- 86 25 5824 3997
- Website
- gempharmatech.com
About Gempharmatech Co. Ltd. A
GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, knock-in mouse, point-mutation mouse, transgenic mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testing, germ-free and microbiome, cell lines and customization, custom breeding, animal quality testing, and other services. The company has a strategic alliance with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the discovery of new therapeutic antibodies. The company was founded in 2017 and is headquartered in Nanjing, China.
Gempharmatech Co. Ltd. A management
6- Dr. Xiang Gao Ph.D.President & Chairman of the Board · born 1963
- Dr. Jing Zhao Ph.D.GM & Director · born 1981
- Mr. Yiou WangCFO & Board Secretary · born 1984
- Yekun LiuAccounting Supervisor
- Ms. Hongyan SunCore Technical Personnel · born 1987
- Mr. Juan LiangCore Technical Personnel · born 1983